Radient Pharmaceuticals' China-Based Subsidiary Jade Pharmaceuticals Signs Letter of Intent to Acquire Shanxi Baotai ...

28 July 2010, 5:51 am

TUSTIN, CA--(Marketwire - July 28, 2010) - Radient Pharmaceuticals Corporation (RPC) ( NYSE Amex : RPC ) announced today its China-based subsidiary Jade Pharmaceuticals Inc. (JPI) signed a letter of intent (LOI) under which JPI will acquire Shanxi BaoTai Pharmaceutical Co., Ltd. (BaoTai), a privately owned pharmaceutical manufacturing company located in Taiyuan China, through a non-taxable ...... Read More »

More Topics from "News"

• Global Marketing Resources Offers Low Cost, Performance Based Local Search Marketing Packages for Small Businesses
• Viridistor Adds Conference Session Materials Management in Upgrade of USB-Based 'Presenter(TM)' Software for Green Box ...
• Radient Pharmaceuticals Announces the Launch of a Spanish Language Website to Support Onko-Sure Sales in Latin America ...
• Radient Pharmaceuticals Announces the Launch of a Spanish Language Website to Support Onko-Sure Sales in Latin America ...
• M Line Holdings, Inc. Announces Positive Results for the Fourth Quarter of Our 2010 Financial Year
• Leach: Stepping up to sponsor 'Broadway'
• Avenged Sevenfold to Chat With Fans Who Have Purchased Nightmare on USTREAM.TV This Thursday, July 29th
• Avenged Sevenfold to Chat With Fans Who Have Purchased Nightmare on USTREAM.TV This Thursday, July 29th
• M Line Holdings, Inc. Announces the Attendance at the FSX Conference